Article Details
Retrieved on: 2025-10-01 14:10:16
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
In 2023 the single-dose monoclonal antibody nirsevimab (Beyfortus) was approved for use in young infants during their first respiratory syncytial ...
Article found on: www.jwatch.org
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here